A Phase 3 interventional study of IV Vancomycin plus IV Aztreonam and Ceftaroline in Bacterial Infections, sponsored by Forest Laboratories. Completed at 52 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-14.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 181 studies in Bacterial Infections with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Bacterial Infections · United States.
Among the 181 studies in Bacterial Infections with a site in United States, this one is the 13th largest by enrollment of the 151 interventional ones that give a count, is one of 9 that started in 2007, is one of 24 in phase 3, and was the 25th registered.
586 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
Browse Bacterial Infections studies →12 of the 181 studies in Bacterial Infections with a site in United States are open now. Recruiting first, the newest first:
Nanopath, Inc · Sites in United States
Ages 18+ · Women only
Bausch Health Americas, Inc. · Sites in United States
Ages 6–12
Karius, Inc. · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Ages 18+
Baxis Pharmaceuticals, Inc. · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 56 Bacterial Infections studies recruiting now, 38 (68%) set no upper age limit and 13 (23%) stop at 75 or younger; 18 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
181 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 67 · Phase 2 27 · Phase 3 24 · Phase 4 15
First in 1997; this study’s year is marked. 9 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 698 is above the median of 84 across 383 interventional studies indexed under Bacterial Infections.
Median enrollment 62 across the 151 interventional studies, 200 across the 29 observational. Of the 160 that completed or were terminated, 58 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
102 of 181 have an industry lead sponsor. The 10 most frequent:
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
AbbVie has 9 studies filed under Bacterial Infections — fewer than ten, so there is no comparison to draw.
7 of the studies in Bacterial Infections with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07607470Nanopath, IncLarge Algorithm Setting and Validation Study | 2026-12 |
| NCT06070688The University of Texas Health Science Center, HoustonAn Adjunct Test Distinguishing Bacterial From Viral Etiology Improves Resource Utilization and Efficiency in the ED. | 2026-12-31 |
| NCT07285785Bausch Health Americas, Inc.Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea | 2027-04-20 |
| NCT05846399University of Missouri-ColumbiaCAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE) | 2027-07-01 |
| NCT07371429GlaxoSmithKlineA Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics | 2027-08-23 |
Add all 7 to your calendar (.ics) → With an account.
Among the 181 studies in Bacterial Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of complicated skin infections in adults.
Additional purpose of the study is to compare ceftaroline effectivity versus Vancomycin plus Aztreonam in the treatment of complicated skin infections in adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Ceftaroline
Drug: IV Vancomycin plus IV Aztreonam
Drug pages: VancomycinStudies of VancomycinVancomycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AztreonamStudies of AztreonamAztreonam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
Also known as: Active Comparator
600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
Also known as: Experimental
Clinical Cure Rate at Test of Cure (TOC) (MITT Population)
Cure: Total resolution of all signs and symptoms of the baseline infection, or improvement of the infection such that no further antimicrobial therapy was necessary. Failure: Requirement of alternative antimicrobial therapy for primary infection of cSSSI due to inadequate response, recurrence, new infection at the same site; treatment-limiting adverse event (AE); requirement for surgery due to failure of study drug; diagnosis of osteomyelitis after Study Day 8; or death caused by cSSSI. Indeterminate: Inability to determine an outcome
Time frame: 8-15 days after the end of treatment
Clinical Cure Rate of Ceftaroline Compared With That of Vancomycin Plus Aztreonam Treatment at TOC in the Clinically Evaluable (CE) Population
Time frame: 8-15 days after last dose of study drug
Microbiological Success Rate at the TOC Visit
Time frame: 8-15 days after last dose of study drug
Clinical Response at the End of Therapy (EOT) Visit
Time frame: Last day of study drug administration
Clinical and Microbiological Response by Pathogen at the TOC Visit
Time frame: 8-15 days after last dose of study drug
Clinical Relapse at the Late Follow Up (LFU) Visit
Time frame: 21 to 35 days after the last dose of study drug
Microbiological Reinfection or Recurrence at the LFU Visit
Time frame: 21 to 35 days after the last dose of study drug
Assess Safety
Comparisons of the number of participants with Adverse Events
Time frame: First dose of study drug through TOC visit
Patients were recruited worldwide from February 2007 to November 2007
| Milestone | Ceftaroline Fosamil for Injection | IV Vancomycin Plus IV Aztreonam |
|---|---|---|
| Started | 351 | 347 |
| Completed | 329 | 317 |
| Not completed | 22 | 30 |
| Withdrew: Withdrew consent | 3 | 4 |
| Withdrew: Death | 3 | 0 |
| Withdrew: Noncompliance | 1 | 2 |
| Withdrew: Request of sponsor or investigator | 0 | 2 |
| Withdrew: Diagnosis of osteomyelitis | 0 | 1 |
| Withdrew: Other | 15 | 21 |
Cure: Total resolution of all signs and symptoms of the baseline infection, or improvement of the infection such that no further antimicrobial therapy was necessary. Failure: Requirement of alternative antimicrobial therapy for primary infection of cSSSI due to inadequate response, recurrence, new infection at the same site; treatment-limiting adverse event (AE); requirement for surgery due to failure of study drug; diagnosis of osteomyelitis after Study Day 8; or death caused by cSSSI. Indeterminate: Inability to determine an outcome
| participants | Ceftaroline Fosamil for Injection | IV Vancomycin Plus IV Aztreonam |
|---|---|---|
| Clinical Cure | 304 | 297 |
| Clinical Failure | 29 | 21 |
| Indeterminate | 18 | 29 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Comparisons of the number of participants with Adverse Events
Results for this outcome have not been posted.
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ceftaroline Fosamil for Injection | — | 16/351 (4.6%) | 128/351 (36.5%) |
| IV Vancomycin Plus IV Aztreonam | — | 12/347 (3.5%) | 162/347 (46.7%) |
| Event | Ceftaroline Fosamil for Injection | IV Vancomycin Plus IV Aztreonam |
|---|---|---|
| CellulitisInfections and infestations | 2/351 | 1/347 |
| Cardiac failure congestiveCardiac disorders | 1/351 | 1/347 |
| Coronary artery diseaseCardiac disorders | 0/351 | 1/347 |
| ConstipationGastrointestinal disorders | 0/351 | 1/347 |
| Generalized edemaGeneral disorders | 0/351 | 1/347 |
| HypersensitivityImmune system disorders | 1/351 | 1/347 |
| Viral infectionInfections and infestations | 0/351 | 1/347 |
| Wound infectionInfections and infestations | 0/351 | 1/347 |
| Bronchial carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/351 | 1/347 |
| SyncopeNervous system disorders | 0/351 | 1/347 |
| Event | Ceftaroline Fosamil for Injection | IV Vancomycin Plus IV Aztreonam |
|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 11/351 | 29/347 |
| NauseaGastrointestinal disorders | 20/351 | 16/347 |
| HeadacheNervous system disorders | 18/351 | 13/347 |
| Pruritus generalizedSkin and subcutaneous tissue disorders | 13/351 | 16/347 |
| DiarrheaGastrointestinal disorders | 12/351 | 11/347 |
| RashSkin and subcutaneous tissue disorders | 12/351 | 8/347 |
| VomitingGastrointestinal disorders | 9/351 | 9/347 |
| InsomniaPsychiatric disorders | 5/351 | 9/347 |
| PyrexiaGeneral disorders | 4/351 | 9/347 |
| ErythemaSkin and subcutaneous tissue disorders | 3/351 | 9/347 |
| Age, Continuous(years) | Ceftaroline Fosamil for Injection | IV Vancomycin Plus IV Aztreonam | Total |
|---|---|---|---|
| Mean | 49.2 ± 17.17 | 47.2 ± 17.01 | 48.2 ± 17.10 |
| Age, Customized(participants) | Ceftaroline Fosamil for Injection | IV Vancomycin Plus IV Aztreonam | Total |
|---|---|---|---|
| >=65 years | 57 | 72 | 129 |
| <18 years | 0 | 0 | 0 |
| >=18 years and < 65 years | 294 | 275 | 569 |
| Sex: Female, Male(Participants) | Ceftaroline Fosamil for Injection | IV Vancomycin Plus IV Aztreonam | Total |
|---|---|---|---|
| Female | 131 | 129 | 260 |
| Male | 220 | 218 | 438 |
| Race/Ethnicity, Customized(participants) | Ceftaroline Fosamil for Injection | IV Vancomycin Plus IV Aztreonam | Total |
|---|---|---|---|
| Non-Hispanic | 268 | 270 | 538 |
| Hispanic | 83 | 77 | 160 |
The record gives a start of Feb 2007, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2010, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ceftaroline